Talus Bio
Discovering drugs that target the DNA regulome
Seattle, United States · Founded 2020 · $21.7M raised
- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Founded
- 2020
- Website
- talus.bio
- Total Funding
- $21.7M
- Last Round
- $11.2M Venture RoundAug 2024
- Rounds
- 4
About
We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.
Summary
Talus Bio is a Biotech company based in Seattle, United States, founded in 2020. It has raised $21.7M in total across 4 rounds, most recently a $11.2M Venture Round round in Aug 2024. Investors include National Cancer Institute.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Global contract research organization providing comprehensive drug development and laboratory ser...